Clinical Trial Update: Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib [Phase 2]

View source ↗

Summary

A Phase 2 trial of Alkotinib capsules in ALK-positive non-small cell lung cancer patients previously treated with Crizotinib has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Alkotinib (alkotinib)

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: ALK-positive Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED